X0202 4 2006-10-23 0001298521 Trubion Pharmaceuticals, Inc TRBN 0001365618 Hove Anders D C/O VENROCK ASSOCIATES 30 ROCKEFELLER PLAZA, ROOM 5508 NEW YORK NY 10112 1 0 1 0 Common Stock 2006-10-23 4 C 0 302527 A 302527 I By Fund Common Stock 2006-10-23 4 P 0 5840 13.00 A 308367 I By Fund Common Stock 2006-10-23 4 C 0 1483474 A 1483474 I By Fund Common Stock 2006-10-23 4 P 0 28637 13.00 A 1512111 I By Fund Common Stock 2006-10-23 4 C 0 36450 A 36450 I By Fund Common Stock 2006-10-23 4 P 0 704 13.00 A 37154 I By Fund Stock Option (Right to Buy) 13.78 2006-10-23 4 A 0 12500 A 2016-10-23 Common Stock 12500 12500 D Series B Preferred Stock 2006-10-23 4 C 0 302527 D Common Stock 302527 0 I By Fund Series B Preferred Stock 2006-10-23 4 C 0 1483474 D Common Stock 1483474 0 I By Fund Series B Preferred Stock 2006-10-23 4 C 0 36450 D Common Stock 36450 0 I By Fund Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock was automatically converted into Common Stock on a 1-for-1 basis. Securities held of record by Venrock Partners, L.P., a limited partnership of which Venrock Partners Management, LLC is the General Partner. Anders D. Hove is a Member of Venrock Partners Management, LLC and disclaims beneficial ownership of these securities except to the extent of his pro-rata interest. Securities held of record by Venrock Associates IV, L.P., a limited partnership of which Venrock Management IV, LLC is the General Partner. Anders D. Hove is a Member of Venrock Management IV, LLC and disclaims beneficial ownership of these securities except to the extent of his pro-rata interest. Securities held of record by Venrock Entrepreneurs Fund IV, L.P., a limited partnership of which VEF Management IV, LLC is the General Partner. Anders D. Hove is a Member of VEF Management IV, LLC and disclaims beneficial ownership of these securities except to the extent of his pro-rata interest. Stock Option Grant to purchase 12,500 shares of Trubion Pharmaceuticals, Inc. Common Stock at $13.78 per share, granted on October 23, 2006 under the terms of the Issuer's 2006 Equity Incentive Plan. The option vests annually over three years from the date of grant. Shares of Preferred Stock were convertible into Common Stock at any time and had no expiration date. All outstanding shares of Preferred Stock were automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Not applicable. Anders D. Hove 2006-10-25